Abshagen U W
Pharmaceutical Division, Boehringer Mannheim International, Germany.
Am J Cardiol. 1992 Nov 27;70(17):61G-66G. doi: 10.1016/0002-9149(92)90028-w.
Pharmacokinetic studies show that isosorbide mononitrate is rapidly absorbed after oral administration, reaches peak concentrations within an hour, undergoes no significant first-pass metabolism, and is virtually 100% bioavailable. The half-life is approximately 5 hours, the volume of distribution is 0.62 liter/kg, and the systemic clearance is 115 mL/min. Only 1-2% of an orally administered dose is excreted unchanged in the urine, with the remainder being eliminated as inactive metabolites. Isosorbide mononitrate follows dose-linear kinetics after single and multiple doses. Its pharmacokinetic profile is consistent and highly reproducible and is unchanged in the elderly and in patients with coronary artery disease, renal failure, or liver cirrhosis. An asymmetrical dosage regimen of isosorbide mononitrate has been shown to provide antianginal efficacy for at least 12 hours. Because asymmetrical dosing creates irregular, sawtooth-like changes in plasma concentrations and a fall below a critical threshold level during the night, tolerance does not develop.
药代动力学研究表明,单硝酸异山梨酯口服后吸收迅速,1小时内达到峰值浓度,无明显首过代谢,生物利用度几乎达100%。半衰期约为5小时,分布容积为0.62升/千克,全身清除率为115毫升/分钟。口服剂量中只有1 - 2%以原形经尿液排泄,其余则作为无活性代谢产物被清除。单硝酸异山梨酯在单剂量和多剂量给药后呈剂量线性动力学。其药代动力学特征一致且高度可重复,在老年人以及患有冠状动脉疾病、肾衰竭或肝硬化的患者中无变化。已证明单硝酸异山梨酯的不对称给药方案可提供至少12小时的抗心绞痛疗效。由于不对称给药会使血浆浓度产生不规则的锯齿状变化,且夜间会降至临界阈值水平以下,因此不会产生耐受性。